Please login to the form below

Not currently logged in
Email:
Password:

Relovair on track for filing in mid-2012, says GSK

But once-daily COPD/asthma treatment still struggles to show superiority over Advair

GlaxoSmithKline (GSK) and partner Theravance have completed two more phase III trials of Relovair, their combination therapy for chronic obstructive pulmonary disease (COPD) and asthma, and say they are now gearing up to file for approval later this year.

Relovair (fluticasone furoate and vilanterol) had been developed as a follow-up to GSK's big-selling Seretide/Advair (fluticasone propionate and salmeterol) product, which achieved sales of over £5bn ($7.9bn) last year but has started to slow down.

Patent protection for Advair starts to expire in Europe next year, so GSK is hoping to have Relovair approved and bringing in revenues as quickly as possible, although it argues that the Diskus inhaler used with the product will confer a competitive advantage even after generics enter the market.

Once again however, GSK and Theravance struggled to show that Relovair was unequivocally superior to Advair in COPD.

One phase III trial in this indication showing significantly better effects on respiratory function while another showed a numerical improvement but did not reach statistical significance. That pattern mirrored earlier phase III trial results.

Relovair still has the advantage over Advair of once-daily rather than twice-daily dosing, thanks to the inclusion of 'ultra' long-acting beta agonist (LABA) vilanterol.

GSK and Theravance also said they have completed a pivotal phase III trial in asthma, designed to compare both fluticasone furoate and fluticasone propionate to placebo.

GSK said Relovair would be filed for COPD in the US and Europe in the middle of the year and will also be submitted as a new treatment for asthma in Europe at the same time.

In the US however GSK said it will "continue discussions" with the FDA on its use in asthma, in light of more stringent regulatory requirements for new asthma therapies which have followed recent concerns about the safety of LABA drugs.

26th March 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PAN

PAN specialises in original, enticing, aspirational and engaging digital and print solutions to maximize brand potential (www.influentialcreativity.com) `Influential creativity' is...

Latest intelligence

Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....
Online Physician Communities
How can pharma develop a more customer-centric approach?
Business pressures and customer needs will force pharma to focus on multichannel marketing in the next few years...